Skip to main content
Premium Trial:

Request an Annual Quote

Cue Health Nabs CE Mark for Molecular Point-of-Care COVID-19 Test

NEW YORK ─ Cue Health said on Tuesday that it has received the CE mark for its molecular point-of-care COVID-19 test, clearing it for sale in the European Union and other regions that accept the designation.

The nucleic acid amplification test ─ compact enough to fit in the palm of a hand ─ consists of the single-use Cue Test Cartridge and the Cue Sample Wand, a lower nasal swab for sample collection. It runs on the Cue Health Monitoring System and displays test results on a connected mobile device in about 20 minutes via an app. A reusable, battery-operated reader and the cartridge communicate results directly to the health app, the firm said.

San Diego-based Cue added that US-based K-12 schools, essential businesses, hospitals, physicians' offices, dental clinics, nursing homes, and other congregate-care facilities are already using its COVID-19 test. It is also being used in several states under a program led by the US Department of Defense and the US Department of Health and Human Services.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.